ReviewCureus2026
Ketamine Use for ED Sedation: Pharmacologic Basis, Clinical Applications, and Safety Considerations.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ketamine is a versatile pharmacologic agent whose unique receptor interactions explain its broad applicability in emergency medicine. Its primary mechanism of action is non-competitive antagonism of N-methyl-D-aspartate (NMDA) receptors, which underlies its dissociative, anesthetic, and analgesic properties. By reducing excitatory neurotransmission and limiting glutamatergic activity, ketamine provides effective sedation while helping prevent neurotoxicity. Additional interactions with opioid, monoaminergic, and cholinergic systems contribute to its analgesic and psychotropic effects, reinforcing its neuroprotective and antidepressant potential. Ketamine is rapidly absorbed, crosses the blood-brain barrier efficiently, and is metabolized in the liver by cytochrome P450 enzymes CYP3A4 and CYP2B6 into active metabolites such as hydroxynorketamine. Its short half-life and multiple routes of administration, including IV, intramuscular (IM), and intranasal, allow for flexible use in different clinical contexts. In the ED, ketamine is used for procedural sedation, fracture and dislocation reduction, wound repair, and trauma management. Its dissociative properties ensure adequate analgesia and amnesia while preserving airway reflexes, reducing the need for additional anesthetic agents. It is particularly valuable in pediatric patients, providing effective sedation and pain control with minimal adverse effects. In cases of trauma, burns, or shock, the sympathomimetic activity of ketamine helps maintain cardiovascular tone and perfusion, offering an advantage over opioids, which may cause hypotension or respiratory depression. Adverse reactions are uncommon but may include laryngospasm, hypertension, tachycardia, or psychological emergence phenomena such as agitation or hallucinations. Coadministration of benzodiazepines can mitigate these effects and improve patient comfort during recovery. Standardized dosing protocols, typically 0.15-0.30 mg/kg IV for analgesia and 2-5 mg/kg IM for sedation, ensure both efficacy and safety. Comparative studies indicate that ketamine maintains hemodynamic stability better than etomidate and has a more favorable respiratory profile compared with benzodiazepine-opioid combinations. Overall, ketamine remains a cornerstone agent for emergency procedural sedation due to its rapid onset, reliability, and adaptability across a wide range of patient populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.